Eli Lilly and Company - Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
Links shared publicly online about this topic.
- 1,862total visits
Eli Lilly and Company - Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
Eli Lilly and Company - Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
View full resource at newsroom.lilly.com
Tags: Multiple Sclerosis, Eli Lilly and Company
Most Recently Shared on July 29, 2009 at 1:59 pm By:
Lilly - Dirucotide Doesn't Meet Primary Endpoint in Phase 3 MAESTRO-01 Trial in 2dary Progressive MS http://bit.ly/wqQuh
Advertisement
